🩸 Hemoglobin A1C Interpreter

A1C translates to average blood sugar by a simple formula: A1C 7.0% means an estimated average glucose of ~154 mg/dL (8.6 mmol/L), while 6.0% is ~126 mg/dL. Enter your A1C for the eAG, the diagnosis band, and the target context.

How to Use This Interpreter

A1C reflects average blood glucose over ~3 months (red cell lifespan). This tool converts it to eAG and places it on the diagnostic and target scales.

The eAG Formula

The ADAG study (2008) paired continuous glucose monitors with A1C across the range to derive the linear relationship now reported alongside most A1C results. Each 1% of A1C is ~29 mg/dL of average glucose: a memorable and clinically useful slope. The relationship is linear but individual: at any A1C, true average glucose varies ±15-20 mg/dL between people due to red cell lifespan differences ("glycation gap"), which is why two people at 7.0% can have meaningfully different meter averages. A1C is a population-calibrated estimate, not a personal glucose diary.

Worked Example

A1C 7.0%: eAG = 28.7 × 7 − 46.7 = 154.2 mg/dL (8.6 mmol/L): diabetes range, exactly at the general target. A1C 5.9%: eAG = 122.6: prediabetes band. A1C 9.5%: eAG = 226: high, averaging in the 200s, which explains the thirst, urination, and fatigue. I verified the tool's arithmetic. The clinical translation: dropping A1C from 9 to 7 takes average glucose from ~212 to ~154, and the UKPDS showed each 1% A1C reduction cuts microvascular complications ~37%: the number is a lever, not a label.

Diagnosis and Target Bands

Targets individualize: under 7% for most, under 6.5% for young healthy patients when achievable safely, under 8% for frail elderly or limited life expectancy where hypoglycemia harms more than hyperglycemia. Pregnancy targets are tighter (under 6-6.5%). For glucose context, our eAG converter converts both directions, our HOMA-IR calculator measures the insulin resistance behind rising A1C, and our glycemic index chart ranks the foods that move it.

What Distorts A1C

Anything changing red cell lifespan or hemoglobin distorts A1C independently of glucose: anemia and hemoglobinopathies (sickle trait, thalassemia), recent transfusion or blood loss, iron deficiency (falsely raises), pregnancy (falsely lowers), CKD, and some assays' interference. When A1C and meter averages disagree persistently, check fructosamine (2-3 week average, unaffected by red cells) or rely on CGM time-in-range instead. Never intensify therapy on a suspicious A1C without confirming: treating a falsely high number causes real hypoglycemia.

Lowering A1C Safely

The hierarchy: weight loss and activity (most powerful for prediabetes), metformin first-line for most type 2, then GLP-1 agonists and SGLT2 inhibitors (which add weight, cardiac, and kidney benefits), insulin when needed. Speed matters less than safety: dropping A1C fast from very high levels can temporarily worsen retinopathy, and aggressive targets cause hypoglycemia that erases the benefit. Pair every intensification with glucose monitoring adequate to catch lows. The goal is time in range with minimal hypoglycemia, and A1C is one window into it, not the whole house.

If CGM is not available or affordable, paired fingersticks (fasting and 2-hour post-meal) a few days per week still reveal the pattern A1C hides. Some data beats none, and patterns across a week reveal what a single reading cannot. Log fasting, pre-meal, and bedtime values for two weeks before each diabetes visit: the logbook still guides titration when technology is absent.

A1C vs Time in Range: The Modern Pair

Continuous glucose monitors added a metric A1C cannot provide: time in range (TIR), the percentage of readings between 70-180 mg/dL, with a target of 70%+. Two patients at A1C 7.0% can have TIR of 85% (stable, safe) or 55% (swinging between highs and lows): same average, different disease. Guidelines now treat TIR as complementary to A1C, especially for type 1 diabetes and insulin-treated type 2, because hypoglycemia burden is invisible to A1C. The glucose management indicator (GMI) estimates A1C from CGM data, and persistent GMI-A1C gaps flag the glycation variants discussed above. For patients without CGM, structured fingerstick patterns (fasting plus 2-hour post-meal pairs) approximate the picture. The modern standard is both numbers: A1C for the long view, time in range for the lived experience, and treatment adjusted to improve both without trading one for the other.

For informational purposes only, not medical advice. Consult a healthcare professional.